Navigation Links
ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
Date:2/9/2010

nics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other f
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics NV - Q3 2009 Business Update
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
4. ThromboGenics NV Announces Business Update and Half Year Results 2009
5. ThromboGenics NV: Business Update
6. ThromboGenics Announces Business Update and 2008 Full Year Results
7. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
8. ThromboGenics N.V.: Business Update
9. ThromboGenics Announces Half Year Results 2008
10. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
11. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... electricity, to move data would consume much less ... concern as chips, transistor counts rise. , Of ... light emitters, modulators, and detectors emitters are ... for optical chips is molybdenum disulfide (MoS2), which ... single, atom-thick layer. Other experimental on-chip light emitters ...
(Date:9/19/2014)... Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... studies characterizing the analgesic profiles of a series ... receptor agonist molecules. The preclinical research candidates were ... platform. The analgesic properties of kappa ... literature. 1,2 Kappa opioid receptors are expressed ...
(Date:9/19/2014)... 19, 2014 Cereal grain scientists, ... will gather October 5–8, 2014, for the AACC ... Convention Center in Providence, Rhode Island. The comprehensive ... of food scientists, chemists, microbiologists, nutritionists, and those ... production management. To date, 1,000 attendees have registered ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Bipartisan passage ... a bill designed to stimulate development and commercialization of ... being praised by leaders of SPIE, the international ... Revitalizing American Manufacturing and Innovation (RAMI) Act, now moves ... authors have said they are optimistic that it will ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3
... , , , ... 8 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer ... enrolled and patients are currently undergoing treatment and follow-up. The ...
... , , ATLANTA and BRIDGEWATER, N.J. ... pollen, as parents prepare for this year,s back to school they should ... nasal allergies ease into the new school year, the My Xperts(TM) program, ... a team of indoor and outdoor nasal allergy experts to help parents ...
... , NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company update at the Morgan Stanley Healthcare ... p.m. ET. , , Interested parties may ... section of the BioMarin website, www.BMRN.com . A ...
Cached Biology Technology:Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program 2Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program 3Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program 4Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program 5VIDEO: Nasal Allergy Experts Offer Free Advice for Back to School Sneezin' 2VIDEO: Nasal Allergy Experts Offer Free Advice for Back to School Sneezin' 3VIDEO: Nasal Allergy Experts Offer Free Advice for Back to School Sneezin' 4VIDEO: Nasal Allergy Experts Offer Free Advice for Back to School Sneezin' 5VIDEO: Nasal Allergy Experts Offer Free Advice for Back to School Sneezin' 6BioMarin to Present at the Morgan Stanley Healthcare Conference 2
(Date:9/19/2014)... years has adapted to the arctic cold, and then you ... for you. , This is happening to the small white ... called nonylphenol, comes from the use of certain detergents, pesticides ... disruptor, but when entering the worm it has another dangerous ... in its body from cold damage. , Enchytraeus albidus ...
(Date:9/18/2014)... GSA Bulletin study uses tree rings to document ... Wash in northern New Mexico, USA. By determining burial ... investigators were able to precisely date arroyo sedimentary beds ... data with aerial imagery, LiDAR, longitudinal profiles, and repeat ... Arroyos are deep, oversized channels that have vertical or ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... MARC (Minority Access to Research Careers) Program has ... Annual International Conference on Intelligent Systems for Molecular ... on Computational Biology (ECCB), an official conference of ... Vienna, Austria from July 15-19, 2011. These ...
... (CHICAGO) Women with the BRCA1 or BRCA2 gene ... of breast and ovarian cancer, can safely take hormone-replacement ... of their ovaries, according to new research from the ... which will be presented Monday, June 6 during the ...
... Event details: , 4:00 5:00 PM eastern, Monday, June ... The Gulf of Mexico is vital to the United States ... recreational fishery production, shipping, and tourism. Its cultural significance ... inhabitants in the face of disasters has inspired the rest ...
Cached Biology News:Women with BRCA mutations can take hormone-replacement therapy safely after ovary removal 2Women with BRCA mutations can take hormone-replacement therapy safely after ovary removal 3Gulf of Mexico ecosystems 1 year after the Deepwater Horizon 2Gulf of Mexico ecosystems 1 year after the Deepwater Horizon 3
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
...
Biology Products: